Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A Oct 5, 2016
Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa Sep 26, 2016
Abeona Therapeutics Announces Licensing of the AIM(TM) Next Generation AAV Gene Therapy Vector Platform From The University of North Carolina at Chapel Hill Sep 21, 2016
Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of MPS IIIA Gene Therapy Sep 15, 2016
Abeona Therapeutics Enrolls 5th Patient in Phase 1/2 Gene Therapy Clinical Trial for Epidermolysis Bullosa Sep 8, 2016
Abeona Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference Sep 7, 2016
